UPAR Ultra Risk Parity ETF UPAR
15.12 USD +0.07 (+0.45%)
At closeNov 11, 2026, 7:30 PM EST
15.12 0.00 0.00%
After hours · Nov 11, 7:30 PM ET
15.07 Day range 15.12
14.89 52-week range 17.71
- YTD
- -2.22%
- 1 year
- -3.35%
News
benzinga.com Hedge Funds Swap Yen For Dollar In New Carry Trade Strategy: Report Hedge funds shift to U.S. dollar for carry trades after backing away from Japanese yen due to interest rate hike and Fed rate cut expectations.
businesswire.com NorthStar Medical Radioisotopes Provides Updates on Corporate Progress and Upcoming Milestones BELOIT, Wis.--(BUSINESS WIRE)--NorthStar Medical Radioisotopes, LLC, a global innovator in the development, production and commercialization of radiopharmaceuticals used for therapeutic and medical…
businesswire.com Conjugated Monoclonal Antibodies Global Market Research Report 2022 - ResearchAndMarkets.com DUBLIN--(BUSINESS WIRE)--The "Conjugated Monoclonal Antibodies Global Market Report 2022: By Drugs, By Technology, By Application" report has been added to ResearchAndMarkets.com's offering. The…
businesswire.com Conjugated Monoclonal Antibodies Global Market Report 2021: COVID-19 Growth and Change to 2030 - ResearchAndMarkets.com DUBLIN--(BUSINESS WIRE)--The "Conjugated Monoclonal Antibodies Global Market Report 2021: COVID-19 Growth and Change to 2030" report has been added to ResearchAndMarkets.com's offering. The global…
etftrends.com Toroso Launches Leveraged ETF for Investors Seeking More Upside On Tuesday, Toroso Asset Management launched the UPAR Ultra Risk Parity ETF (UPAR), expanding its line-up of risk parity ETFs with a new product aimed at investors looking for more upside. The new…
businesswire.com Real-Time Monitoring of Melanoma Cell Invasion Helps Scientists
Elucidate Key Regulators of Metastasis SAN DIEGO--(BUSINESS WIRE)--A team of Italian scientists reported this week that blocking the interaction between urokinase receptor (uPAR) and formyl peptide receptor type 1 (FPR1) suppresses the…
businesswire.com Onxeo concède à Monopar Therapeutics une licence mondiale
exclusive de Validive®, développé dans le traitement de la mucite orale
sévère PARIS--(BUSINESS WIRE)--Regulatory News: Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen : ONXEO), (« Onxeo » ou la « Société »), société de biotechnologie au stade clinique spécialisée dans le…
businesswire.com Onxeo Grants Exclusive Worldwide License of Validive® Developed
for the Treatment of Oral Severe Mucositis to Monopar Therapeutics PARIS--(BUSINESS WIRE)--Regulatory News: Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), (“Onxeo” or the “Company”), a clinical-stage biotechnology company specializing in the development of…